Centinel Spine has released its second-quarter earnings for 2024, showing record growth from the same period last year.
Its revenue growth comes, in part, due to the expansion of its Prodisc product line used for treating cervical and lumbar spine, according to a July 24 press release.
Here are nine highlights from Centinel Spine's Q2 revenue report:
1. Centinel saw Prodisc total disc replacement revenue of $22.1 million, up 26% year over year.
2. Worldwide Prodisc cervical revenue reached $14.6 million, with 32% year-over-year growth.
3. Centinel saw record U.S. Prodisc cervical revenue, with 42% year-over-year growth.
4. Nearly 600 surgeons in the U.S. are now using Prodisc, representing almost 40% year-over-year growth and sequential quarterly user growth of 10%.
5. This quarter marked the eighth consecutive quarter with surgeon Prodisc user growth.
6. Nearly 7,000 procedures have been completed using Centinel's new Prodisc C Vivo & Prodisc C SK cervical system since limited U.S. release in Q3 2022.
7. Centinel saw record Prodisc C Vivo and Prodisc C SK revenue in Q2 2024, representing nearly 67% and 100% year-over-year growth, respectively.
8. A record number of new surgeons used the Match-the-Disc Prodisc C Vivo and Prodisc C SK cervical system in Q2 2024, increasing the total number of surgeons that have utilized the new system by nearly 140% year over year.
9. Over 75% of the nearly 700 surgeons that have utilized the new system to date are repeat users.